<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1150">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146180</url>
  </required_header>
  <id_info>
    <org_study_id>CHB18.10</org_study_id>
    <nct_id>NCT05146180</nct_id>
  </id_info>
  <brief_title>Interest of Parametric Positron Emission Imaging in the Diagnosis of Infections on Cardiac Valve Prosthesis</brief_title>
  <acronym>PARAVA</acronym>
  <official_title>Interest of Parametric Positron Emission Computed Tomography Imaging in the Diagnosis of Infections on Cardiac Valve Prosthesis : PARAVA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Henri Becquerel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine if early parametric positron emission computed&#xD;
      tomography is useful to diagnose cardiac prosthetic valve infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition to routine examinations (biological and microbiological tests, transesophageal or&#xD;
      transthoracic ultrasound, transesophageal or transthoracic ultrasound, and leukocyte&#xD;
      scintigraphy) of a parametric acquisition during the positron emission computed tomography&#xD;
      parametric acquisition during positron emission computed tomography , this examination being&#xD;
      itself planned in a standard way.&#xD;
&#xD;
      The definitive diagnosis according to the Duke-Li criteria will be established three months&#xD;
      later in a multidisciplinary consultation meeting.&#xD;
&#xD;
      The final diagnosis according to the Duke-Li criteria will be made three months later in a&#xD;
      multidisciplinary consultation meeting, blinded to the results of the parametric positron&#xD;
      emission computed tomography, and with knowledge of the results of the standard positron&#xD;
      emission computed tomography and the entire work-up.&#xD;
&#xD;
      Results and all the complementary work-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of diagnostic value of parametric positron emission computed tomography</measure>
    <time_frame>3 months</time_frame>
    <description>area under the curve of the Ki parameter (and the Vd parameter) as a function of the presence of endocarditis diagnosed during the multidisciplinary consultation meeting at 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between parametric positron emission computed tomography and scintigraphy with labelled leukocytes</measure>
    <time_frame>3 months</time_frame>
    <description>comparison between diagnosis established by parametric positron emission computed tomography and scintigraphy with labelled leukocytes</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Endocarditis</condition>
  <arm_group>
    <arm_group_label>Parametric positron emission computed tomography</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Parametric positron emission computed tomography</intervention_name>
    <description>Patients will undergo parametric positron emission computed tomography in 15 days after the labeled polynuclear scintigraphy</description>
    <arm_group_label>Parametric positron emission computed tomography</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age superior to18 years,&#xD;
&#xD;
          -  Effective contraception for women of childbearing age or negative pregnancy test on&#xD;
             the day of the exam&#xD;
&#xD;
          -  Good general condition. WHO â‰¤ 1&#xD;
&#xD;
          -  Suspicion of endocarditis on a prosthetic heart valve implanted more than 3 months ago&#xD;
&#xD;
          -  Labeled polynuclear scintigraphy performed within a maximum of 15 days before positron&#xD;
             emission computed tomography&#xD;
&#xD;
          -  Standard positron emission computed tomography planned as part of the extension&#xD;
             assessment&#xD;
&#xD;
          -  Informed and signed consent before any specific study procedure.&#xD;
&#xD;
          -  Patient affiliated to the social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of an active cancer in the previous three years&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Poorly controlled diabetic patients&#xD;
&#xD;
          -  Protected adults (under guardians or curators)&#xD;
&#xD;
          -  Impossible decubitus (orthopnea, ...),&#xD;
&#xD;
          -  Hypersensitivity to FDG or to one of the excipients of the radiopharmaceutical.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathieu Chastan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Henri Becquerel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathieu Chastan, MD</last_name>
    <phone>+33276673032</phone>
    <email>mathieu.chastan@chb.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Doriane Richard, PhD</last_name>
    <phone>+33232082985</phone>
    <email>doriane.richard@chb.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathieu Chastan, MD</last_name>
      <email>mathieu.chastan@chb.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Doriane Richard, PhD</last_name>
      <email>doriane.richard@chb.unicancer.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

